Safety Study of a Vaccine (DENV-1 PIV) to Prevent Dengue Disease

United States Army Medical Research and Development Command (USAMRDC)

Status and phase

Completed

Phase 1

Conditions

Dengue Fever

Treatments

Biological: DENV-1 PIV, 5 µg

Biological: DENV-1 PIV, 2.5 µg

Study type

Interventional

Funder types

Other U.S. Federal agency

Identifiers

NCT01502735

IND 14338 (Other Identifier)

WRAIR IRB Protocol # 1856 (Other Identifier)

S-10-0003

HSRRB Protocol #: A-17104 (Other Identifier)

Details and patient eligibility

About

This is a phase 1 study to evaluate the safety of a vaccine (DENV-1 PIV) for the prevention of dengue fever.

Full description

DENV infections can cause self-limited but incapacitating acute illness lasting four to seven days. The illness is characterized by fever, headache, severe pain in muscles, joints, pain behind the eyes, and a rash. DENV infection can be complicated by the development of hemorrhagic fever (DHF) or shock syndrome (DSS), which is manifested by plasma leakage and a bleeding diathesis or frank hemorrhage. DHF is fatal in at least 0.5% of pediatric cases but rarely in adults. People, particularly children, living in hyper-endemic areas who have antibodies from an earlier dengue infection with one serotype are at increased risk for DHF if subsequently infected by another dengue virus serotype.

Currently, no specific anti-viral therapy exists. Therapy is largely supportive. Mosquito control has failed to prevent dengue transmission; therefore, prevention of dengue through vaccination is an important objective of the World Health Organization (WHO) and many national governments, including the United States.

Enrollment

20 patients

Sex

All

Ages

18 to 50 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Males and females 18 years of age or the legal age of consent (whichever is greater) to 50 (inclusive) years of age
Negative screening laboratory test against dengue, Japanese Encephalitis, West Nile, and Yellow Fever viruses
Healthy
All subjects must agree to use contraception or to abstain from sex from enrollment through trial completion
Able to provide informed consent and able to be followed throughout the trial period

Exclusion criteria

History of Flavivirus infection or history of Flavivirus vaccine (experimental or licensed product) including Japanese encephalitis, West Nile virus, Yellow fever, and dengue
Have a known or suspected hypersensitivity or adverse reaction to vaccines
Have received a live-attenuated vaccine within 42 days prior to the initial injection on Day 0 or a subunit or killed vaccine within 30 days of the initial injection on Day 0
Are pregnant or breastfeeding
Known HIV, Hepatitis B and/or Hepatitis C infection
Have any acute illness, including an oral body temperature greater than 100.4°F at the day of vaccination
Have any occupational, social, or medical concerns that would impact subject safety, interfere with protocol adherence, or affect a subject's ability to give informed consent
Have been using immunomodulatory therapy (use of systemic corticosteroids or chemotherapeutics that may influence antibody development) within the past 6 months; medications or nutritional supplements known to or which potentially could affect organ function within 30 days prior to the initial injection
Have received an investigational drug or vaccine or participated in a drug product or vaccine study within a period of 30 days prior to Day 0
Have received or donated blood or plasma within 90 days of Day 0 (or plan on receiving or donating blood or plasma during the study)